NOVATO, Calif, Oct. 17, 2023 (GLOBE NEWSWIRE) — Cyclarity Therapeutics, Inc. (https://cyclaritytx.com), today announced its newly formed Clinical Advisory Board to guide its clinical development of drug candidate UDP-003 for the treatment and prevention of atherosclerosis, primary coronary artery disease, and associated cardiovascular diseases. The Board includes the internationally recognized, […]